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Neovascularization is essential for growth of, and nutrition to,
solid tumours greater than 2 mm in diameter (Folkman, 1985).
Unorganized basement membrane of new capillary endothelial cells
allows intravasation of tumour cells, and a high density of microves-
sels in tumours is associated with their expansion and invasiveness
(Srivastava et al, 1988; Weidner et al, 1991; Macchiarini et al, 1992;
Wakui et al, 1992; Weidner et al, 1993). Neovascularization consists
of the following steps: dissolution of basement membrane by
proteases which are released from the tumour or host cells activated
by tumour-derived angiogenic factors, migration and proliferation
of endothelial cells, and capillary-tube formation (Folkman and
Haudenschild, 1980). Angiogenic factors stimulate the corre-
sponding steps of neovascularization.
Generally speaking, angiogenic factors have been identified as
follows: basic fibroblast growth factor (bFGF), VEGF, placenta
growth factor (PlGF), epidermal growth factor (EGF), trans-
forming growth factor (TGF)-a, TGF-b, platelet-derived growth
factor (PDGF), platelet-derived endothelial cell growth factor
(PD-ECGF), hepatocyte growth factor (HGF), tumour necrosis
factor (TNF)-a, pleiotropin, proliferin, angiogenin, oestradiol,
interleukin (IL)-8, etc. Among them, main factors induced from
tumour cells are bFGF, VEGF, PD-ECGF and IL-8. VEGF was
initially recognized as a vascular permeability factor (34–42 kDa)
which induced tumour ascites (Senger et al, 1983). Afterwards,
VEGF was identified as a vascular permeability factor that is
active in increasing blood vessel permeability, endothelial cell
growth and angiogenesis (Leung et al, 1989). On the other hand,
it was described as having a direct-acting mitogen specific for
vascular endothelial cells (Keck et al, 1989). VEGF is expressed in
tissues with rapid vascular endothelial turnover, i.e. reproductive
organs such as ovary, uterus and placenta (Garrido et al, 1993;
Jackson et al, 1994; Li et al, 1994), and ovarian and uterine
cervical and endometrial cancers (Olson et al, 1994; Guidi et al,
1995; Guidi et al, 1996). In detail, VEGF contributes to angiogenic
potential in premalignant changes (Dobbs et al, 1997), invasive
carcinoma (Guidi et al, 1995) and adenocarcinoma of the cervix
(Tokumo et al, 1998). However, it is unknown which VEGF
subtypes (Houck et al, 1991) contribute to angiogenic potential in
uterine cervical cancers.
To know the potential of growth, invasion and metastasis of
uterine cervical cancer associated with neovascularization, local-
ization of VEGF and microvessel density in tumours were deter-
mined by immunohistochemical staining, the levels of VEGF
subtypes were determined by Western blot analysis and by a sand-
wich enzyme immunoassay, and the levels of VEGF subtype
mRNAs were determined by reverse transcription polymerase
chain reaction (RT-PCR)–Southern blot analysis in uterine cervical
cancers and uterine normal cervices as controls. The relation
between VEGF subtype expressions and microvessel density,
histological types and clinical stages of uterine cervical cancers
was analysed.
PATIENTS AND METHODS
Patients
Agreements for the following studies were obtained from all
patients and the Research Committee for Human Subjects, Gifu
University School of Medicine. A total of 150 patients ranging
from 32 to 83 years of age underwent hysterectomy for leiomyoma
or uterine cervical cancer at the Department of Obstetrics and
Gynecology, Gifu University School of Medicine, between March
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Correspondence to: J Fujimoto1994 and December 1997. None of the patients received any
preoperative therapy. A part of the tissues of uterine cervical
cancers and normal uterine cervices as controls was obtained
immediately after hysterectomy and snap-frozen in liquid nitrogen
to determine the levels of VEGF and its mRNA expression, and a
neighbouring part of the tissues was submitted for histopatho-
logical study. The clinical staging was determined by International
Federation of Obstetrics and Gynecology (FIGO) classification
(FIGO News, 1989).
Immunohistochemistry
Four-micrometer sections were cut from formalin-fixed paraffin-
embedded tissue with a microtome and dried overnight at 378C on
a silanized slide (Dako, Carpinteria, CA, USA). Samples were
deparaffinized in xylene at room temperature for 80 min and
washed with a graded ethanol–water mixture and then with
distilled water. The samples for VEGF were soaked in a citrate
buffer and then microwaved at 1008C for 10 min, and those for
factor VIII-related antigen were treated with 0.3 mg ml21 trypsin in
a phosphate buffer at room temperature for 20 min. The protocol
for DAKO LSAB2 Kit, Peroxidase (Dako) was followed for each
sample. In the described procedure, rabbit anti-human VEGF
antigen VEGF(147) (200 mg ml21, Santa Cruz, CA, USA), and
rabbit anti-factor VIII-related antigen (Zymed, San Francisco, CA,
USA) as the first antibodies were used at dilutions of 1:100 and 1:2
respectively. Vascular density was evaluated with microvessel
counting (Maeda et al, 1996). The addition of the first antibody
was omitted in the protocol for negative controls.
Western blot analysis for human VEGF
Tissues (wet weight: 10–20 mg) were homogenized in WB-HB
buffer (10 mM) Tris–HCl, pH 7.4, 150 mM sodium chloride (NaCl),
0.5% Triton X-100 and 0.2 mM phenylmethylsulphonyl fluoride)
with a Polytron homogenizer (Kinematics, Lucerne, Switzerland).
The protein concentration of samples was measured by the method
of Bradford (Bradford, 1976). Each sample (25 ml) containing
100 mg of protein was added to 25 ml of a sample buffer (12.5 mM
Tris–HCl, pH 6.8, 2% glycerol, 0.4% sodium dodecyl sulphate
(SDS) and 1.25% 2-mercaptoethanol) and analysed by 7.5% SDS
polyacrylamide gel electrophoresis (SDS-PAGE) under non-
reducing conditions. The gel was transferred to a nitrocellulose
membrane (Hybond ECL Western; Amersham, Arlington Heights,
IL, USA). The membrane was blocked with 5% milk (from dehy-
drate) in a blocking buffer (20 mM Tris–HCl, pH 7.6, 137 mM NaCl
and 0.1% Tween-20), incubated with rabbit anti-human VEGF anti-
body (1:1000) (Oncogene Research Products, Cambridge, MA,
USA), washed, and then incubated with peroxidase-linked species-
specific whole antibody, anti-rabbit immunoglobulin from donkey
(1:2000) (Amersham, Buckinghamshire, UK). Specific bands
were detected with electrochemiluminescence (ECL) reagent
(Amersham, Arlington Heights, IL, USA), and X-ray film was
exposed on the membrane at room temperature for 10 min.
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Figure 1 Schematic representation of human VEGF isoforms. exon 1–5, exons 1, 2, 3, 4 and 5; S, sense primer for human VEGF cDNA; AS, antisense primer
for human VEGFEnzyme immunoassay for determination of human
VEGF antigen
All steps were carried out at 48C. Tissues (wet weight: 10–20 mg)
were homogenized in HG buffer (5 mM Tris–HCl, pH 7.4, 5 mM
NaCl, 1 mM calcium chloride, 2 mM ethyleneglycol-bis-[b-
aminoethyl ether]-N,N,N¢,N¢-tetraacetic acid, 1 mM magnesium
chloride (MgCl2), 2 mM dithiothreitol (DTT), 25 mg ml21 aprotinin
and 25 mg ml21 leupeptin) with a Polytron homogenizer
(Kinematics). This suspension was centrifuged in a microfuge at
12 000 rpm for 3 min to remove the nuclear pellet. The protein
concentration of samples was measured by the method of Bradford
to standardize VEGF antigen levels (Bradford, 1976).
VEGF antigen levels in the samples were determined by a sand-
wich enzyme immunoassay using a Human VEGF Assay Kit-IBL
(Immuno Biological Laboratories, Gunma, Japan). The levels of
VEGF were standardized with the corresponding cellular protein
concentrations.
RT-PCR to amplify VEGF mRNA
The oligodeoxynucleotides of specific primers in PCR were
synthesized according to the published information (cDNA for
VEGF (Houck et al, 1991) as shown in Figure 1 and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) (Arcari et al, 1984))
as follows:
sense primer for VEGF mRNA: 5¢-AGGCCAGCACATAG-
GAGAGA-3¢ (in exon 4)
antisense primer for VEGF mRNA: 5¢-ACCGCCTCG-
GCTTGTCACAT-3¢ (in exon 8)
sense primer for GAPDH mRNA: 5¢-TGAAGGTCGGAGT-
CAACGGATTTGGT-3¢ (in exon 2)
antisense primer for GAPDH mRNA: 5¢-CATGTGGGCCAT-
GAGGTCCACCAC-3¢ (in exon 8).
Total RNA was isolated from the cells by the acid guanidium thio-
cyanate–phenol–chloroform extraction method (Chomczynski and
Sacchi, 1987). Total RNA was reverse transcribed with Moloney
murine leukaemia virus reverse transcriptase (MMLV-RTase, 200
units, Gibco BRL, Gaithersburg, MD, USA) in a buffer of 20 mM
Tris–HCl, pH 8.4, 50 mM potassium chloride (KCl), 2.5 mM
MgCl2, 0.1 mg ml21 bovine serum albumin, 10 mM DTT and
0.5 mm deoxynucleotides to generate cDNAs using random
hexamer (50 ng, Gibco BRL) at 378C for 60 min. The RT reaction
mixture was heated at 948C for 5 min to inactivate MMLV-RTase.
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Figure 2 Signal intensity curve for VEGF mRNA level in a series of reverse
transcribed-total RNA of normal uterine cervix by RT-PCR–Southern blot
analysis. A series amount of PCR templates were prepared from reverse
transcribed total RNA in uterine normal cervices. PCR–Southern blots were
carried out as described in Materials and Methods. (A) A representative
Southern blot for the expressions of VEGF and GAPDH mRNAs. (B) The
levels of VEGF mRNA expression in normal uterine cervix were assigned
as arbitrary units/GAPDH mRNA (AU/GAPDH mRNA). Data are the
mean6 s.d. of nine determinations
AB
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Figure 3 Immunohistochemical staining for VEGF in uterine cervical cancers. Positive staining is seen dominantly in the cytoplasm of the cancer cells, and
faintly in interstitial cells. The intensity of VEGF staining was significantly stronger in adenocarcinomas (B) than in squamous cell carcinomas (A) (original
magnification ´200)Ten cycles of PCR for VEGF mRNA, consisting of denaturation
for 1 min at 948C, annealing for 1 min at 558C, and extension for
1 min at 728C, were carried out with reverse transcribed cDNA,
0.1 mM specific primers and Vent DNA polymerase (New England
Biolabs, Beverly, MA, USA) in a buffer of 10 mM KCl, 20 mM
Tris–HCl, pH 8.8, 10 mM (NH4)2SO4, 2 mM MgSO4, 0.1% Triton
X-100 and 0.15 mM deoxynucleotide phosphates using the IWAKI
thermal sequencer TSR-300 (Iwaki Glass, Tokyo, Japan).
Additionally, 23 cycles of PCR for VEGF and GAPDH mRNAs as
an internal standard were done in the same manner.
The signal intensity curve for mRNA expression is necessary
for an accurate measurement of the mRNA by RT-PCR. A series
of PCR templates (1.5 mg, 3 mg, 6 mg, 12 mg, 24 mg and 48 mg
reverse transcribed-total RNA) were prepared to get the signal
intensity curve of the mRNA levels on RT-PCR–Southern blot.
The signal intensity curve for VEGF and GAPDH mRNA levels
ranging from 1.5 mg to 24 mg reverse transcribed-total RNA of
normal uterine cervix by RT-PCR–Southern blot was linear
(Figure 2). Therefore, semiquantative alternation of VEGF mRNA
levels standardized with GAPDH mRNA levels was thought to be
reliable. Additionally, the template for negative controls of RT-
PCR was not reverse transcribed. The Southern blot revealed no
band in the negative control for each sample (data not shown).
Southern blot analysis for quantities of VEGF mRNA
expression
PCR products were applied to 1.2% agarose gel, and electro-
phoresis was performed at 50–100 V. PCR products were capil-
lary-transferred to an Immobilon transfer membrane (Millipore
Corp., Bedford, MA, USA) for 16 h. The membrane was dried at
808C for 30 min, and was UV-irradiated to tightly fix PCR prod-
ucts. PCR products on the membrane were prehybridized in a
buffer of 1 M NaCl, 50 mM Tris–HCl pH 7.6 and 1% SDS at 428C
for 1 h, and hybridized in the same solution with the biotinylated
oligodeoxynucleotide probes synthesized from the sequences of
VEGF and GAPDH cDNAs between the specific primers at 658C
overnight as follows: probe for VEGF gene: 5¢-CAGCACAA-
CAAATGTGAATG-3¢ (in exon 4); probe for GAPDH gene:
5¢-GCTCACTGGCATGGCCTTCC-3¢ (in exon 8).
Specific bands hybridized with the biotinylated probes were
detected with Plex Luminescent Kits (Millipore Corp.), and X-ray
film was exposed on the membrane at room temperature for
10 min. The quantification of Southern blot was carried out with
Bio Image (Millipore, Ann Arbor, MI, USA). The intensity of
specific bands was standardized with that of GAPDH mRNA.
Statistics
The levels of VEGF and its mRNA were measured from three
parts of the same tissue in triplicate. Statistical analysis was
performed with Student’s t-test; differences were considered
significant when P was less than 0.05.
RESULTS
Immunohistochemical staining for VEGF (n 5 120) was carried
out to study VEGF localization in the tumours, and the strength of
staining was correlated with VEGF levels measured by a sandwich
enzyme immunoassay. As shown in Figure 3, positive staining is
seen dominantly in the cytoplasm of the cancer cells, and faintly in
interstitial cells. The intensity of VEGF staining was significantly
stronger in adenocarcinomas than in squamous cell carcinomas.
There was a significant correlation between VEGF levels and
microvessel count, as shown in Figure 4 (y 5 0.034 x 1 9.049,
r 5 0.64.)
To analyse which subtypes of VEGF (as shown in Figure 5)
induce angiogenesis, the following studies were carried out. In
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Figure 4 Correlation between VEGF level and microvessel count
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Figure 5 Western blot analysis for the expression of VEGF and Southern
blot analysis for the expression of VEGF mRNA in uterine cervical cancers.
Case 1: normal uterine cervix; Case 2: Stage I, LNK; Case 3: Stage II, K;
Case 4: Stage III, SNK; Case 5: Stage IV, AD. K, keratinizing squamous cell
carcinoma; LNK, large cell non-keratinizing squamous cell carcinoma; SNK,
small cell non-keratinizing squamous cell carcinoma; AD, adenocarcinoma.
Histological types and clinical stages of uterine cervical cancers are
according to International Federation of Gynecology and Obstetrics [FIGO]
(FIGO News, 1989)uterine cervical cancers and normal uterine cervices, mainly
VEGF165 and VEGF121 and their mRNAs were detected by Western
blot and RT-PCR–Southern blot respectively. VEGF189 and its
mRNA were only remarkably faintly detected, and VEGF206 and its
mRNA were not detected. The two main subtypes and their mRNAs
expressed in uterine cervical cancers and normal uterine cervices are
shown in parallel in Figure 5. The simultaneous determinations of
total VEGF level by a sandwich enzyme immunoassay and subtype
mRNAs with RT-PCR–Southern blot is believed to provide enough
information to reliably identify the population of subtype protein
expressions.
Among the four subtypes of VEGF, the populations of VEGF165
and VEGF121 were dominant in normal uterine cervices and uterine
cervical cancers. There was no significant difference in the levels
of VEGF, and VEGF165 and VEGF121 mRNAs among normal
uterine cervices and uterine cervical cancers classified according
VEGF in endometrial cancers 831
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Figure 6 Levels of VEGF and its mRNA in uterine cervical cancers
classified according to histological types. The levels of VEGF and its mRNA
were determined by a sandwich enzyme immunoassay and RT-
PCR–Southern blot analysis respectively. The mRNA level in normal uterine
cervices as controls was assigned as AU/GAPDH mRNA. Histological types
of uterine cervical cancers are according to FIGO. Each result is the
mean 6 s.d. of nine determinations. The number in l l indicates each case
in which VEGF and its mRNA were expressed relatively high
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Figure 7 Levels of VEGF and its mRNA in uterine cervical cancers
classified according to clinical stages. Clinical stages of endometrial cancer
are according to FIGO. Each result is the mean 6 s.d. of nine
determinations. s s and s, adenocarcinoma of the cervix. The number in s s
indicates each case in which VEGF and its mRNA were expressed relatively
highto histological types. However, they were remarkably higher in
some adenocarcinomas of the cervix than in other cases, including
normal cervices (Figure 6). Similarly, there was no significant
difference in their levels among normal uterine cervices and
uterine cervical cancers classified according to clinical stages.
However, their levels were remarkably higher in some stages II
and III/IV adenocarcinomas of the cervix than in other cases,
including normal cervices (Figure 7).
DISCUSSION
Newly developed capillary network formation from the original
vessel is designated as neovascularization. Generally, turnover of
capillary endothelial cells is extremely slow, to the order of
months or years in physiological neovascularization, while the
turnover in ovary and uterine endometrium is rapidly altered along
with ovarian cycle. The turnover with malignant transformation
becomes rapid, which might contribute to the acceleration of
tumour growth (Denekamp, 1984).
Expression of the tumour cell-derived angiogenic factors,
bFGF, VEGF, PD-ECGF and IL-8, may be specific for each
tumour and dependent on the process of tumour growth and
spreading. The levels of bFGF and its mRNA were higher in
advanced primary uterine cervical cancers, regardless of histolog-
ical type (Fujimoto et al, 1997). The levels of PD-ECGF and its
mRNA were higher and in a wider range in uterine cervical
cancers, especially squamous cell carcinomas, regardless of clin-
ical stage (Fujimoto et al, 1999). VEGF, secreted from many
tumours, does not contribute to tumour growth via an autocrine
pathway to tumour cells, but via a paracrine pathway to
surrounding microvessels (Berkman et al, 1993). Furthermore, it
facilitates metastasis via neovascularization (Warren et al, 1995).
In the present study, it is demonstrated that VEGF dominantly
expresses in the cancer cells, and VEGF levels correlate to
microvessel density in uterine cervical cancers.
Among VEGF subtypes, VEGF189 is closely associated with
progression of non-small-cell lung cancer (Oshika et al, 1998).
Coexpression of VEGF121, VEGF165 and especially VEGF189 was
correlated with liver metastasis and poor prognosis in colon cancer
(Tokunaga et al, 1998). Only VEGF165 protein was detected in
normal and malignant breast tissues (Scott et al, 1998). VEGF165
was elevated in all stages of ovarian carcinoma via angiogenic
activity (Fujimoto et al, 1998a). Intracerebral tumour-associated
haemorrhage was caused by overexpression of VEGF121 and
VEGF165 but not VEGF189 (Cheng et al, 1997). VEGF165 and
VEGF121 in some uterine endometrial cancers contribute to the early
process of advancing of malignancy via angiogenic activity
(Fujimoto et al, 1998b). In the present study, the populations of
VEGF165 and VEGF121 were dominant in uterine cervical cancers.
VEGF145 expression was demonstrated in several cell lines derived
from the female reproductive system, and might contribute unique
biological properties distinct from those of previously characterized
VEGF isoforms (Poltorak et al, 1997). We noticed that in approxi-
mately 10% of cases the band of VEGF165 was relatively thick, and
might involve the isoform VEGF145. However, in uterine cervical
cancers, the dominant expressed isoforms were definitely VEGF165
and VEGF121. Therefore, the manner of VEGF subtype expression
might depend upon tissue specificity, and the levels of VEGF165 and
VEGF121 might be essential to total angiogenic activity supplied
from VEGFs. The levels of VEGF and VEGF165 and VEGF121
mRNAs were higher in some relatively advanced adenocarcinomas
of the cervix. Therefore, the elevation of VEGF165 and VEGF121
might contribute to the relatively late advancing via angiogenic
activity in some adenocarcinomas of the cervix. This indicates that
angiogenic inhibitors (Folkman and Ingber, 1987; Fujimoto et al,
1989; Ingber et al, 1990) on the new capillary formation might be
effective as therapy for some adenocarcinomas of the cervix apart
from a direct anti-tumoural effect on cancer cells.
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